Concepedia

Author

Maciej Cabanski

Novartis (Switzerland)ORCID

Also Known As

M. Cabanski, Maciej Cabanski

18

Publications

759

Citations

10

H-Index

14

Concepts

All Affiliations

Novartis (Switzerland)Novartis (United States)AstraZeneca (United States)Charité - Universitätsmedizin BerlinCaprion (Canada)
MC

About

Maciej Cabanski is an author at Novartis (Switzerland) specializing in medical laboratory science, chromatography, and cytometry.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Engineering

1

1

12

2

Medicine

1

1

12

3

Biomedical Engineering

1

1

12

4

Medical Laboratory Science

1

1

12

5

Pathology

1

1

12

Maciej Cabanski

×

9

Publications

722

Citations

9

H-Index

YearCitations

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

V. Koneti Rao, Sharon Webster, Virgil A. S. H. Dalm,

Blood

2017

276

Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Thomas Dörner, Maximilian Posch, Yue Li,

Annals of the Rheumatic Diseases

2019

189

Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways

Ewa Surdziel, Maciej Cabanski, Iris Dallmann,

Blood

2011

90

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

Martin Kaul, Peter End, Maciej Cabanski,

Clinical and Translational Science

2021

74

Cyt‐Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2018 Conference Workshops

Kamila Czechowska, Joanne Lannigan, Lili Wang,

Cytometry Part A

2019

26

OP0250 A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary sjÖgren's syndrome

Thomas Dörner, Margit Zeher, Ute Laessing,

Annals of the Rheumatic Diseases

2018

21

Transcriptional profiling and targeted proteomics reveals common molecular changes associated with cigarette smoke-induced lung emphysema development in five susceptible mouse strains

Maciej Cabanski, Brett Fields, Stéphanie Boué,

Inflammation Research

2015

20

Abstract 3449: Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction

Gérald Gavory, Mahmoud Ghandi, Anne-Cecile d’Alessandro,

Cancer Research

2023

14

Flow cytometric method transfer: Recommendations for best practice

Maciej Cabanski, Teri Oldaker, Jennifer J. Stewart,

Cytometry Part B Clinical Cytometry

2020

12

Page 1